180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant

180 Life Sciences Corp. ATNF filed a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the problem of obesity and weight management.

CBD has been shown to reduce inflammation and stimulate satiety, but establishing the details of the mode of action has been hampered by CBD binding over 50 different biological receptors. The recent clinical success of GLP-1 agonists in stimulating satiety and resultant weight reduction in patients with type 2 diabetes led 180LS scientists to hypothesize that CBD and GLP-1 might stimulate a common therapeutic pathway. The dramatically different structures of the two drugs make binding a common receptor unlikely, but the company speculates that the two compounds could stimulate a common neurological pathway between the gut and the brain.

GLP-1 signals satiety to the brain through stimulation of specific GLP-1 receptors expressed on the afferent arm of the vagus nerve. Scientists at 180 Life Sciences plan to collaborate with neurological experts to investigate whether CBD stimulates satiety through a neural pathway involving the vagus nerve. Negotiations are currently underway with third party scientists for a research collaboration to design and execute testing of the company’s theory. This research collaboration is designed to determine whether CBD and GLP-1 stimulate a common signal for satiety to the brain. If so, CBD may represent a significantly less expensive alternative with fewer side effects than GLP-1 agonists for weight reduction.

“We are excited about the opportunity to collaborate with scientists who are experts in vagus nerve signaling,” stated Dr. James Woody, CEO of 180 Life Sciences, who continued, “We expect, if the hypothesis is correct, this research could provide support to proceed to human clinical trials. Our chief scientific officer, Dr. Jonathan Rothbard, was involved in the Amylin discovery work of the GLP-1 pathway and has extensive scientific knowledge of how synthetic CBD compounds might induce satiety through stimulating the vagus nerve.”

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Benzinga edit with photos by Matthias Zomer on Pexels and squarefrog on Pixabay